{"id":"efavirenz-emtricitabina-tenofovir","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Dizziness and CNS effects"},{"rate":"10-20","effect":"Rash"},{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"10-20","effect":"Abnormal dreams/nightmares"},{"rate":"1-5","effect":"Renal dysfunction (tenofovir-related)"},{"rate":"variable","effect":"Bone density loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the enzyme HIV uses to convert its RNA genome into DNA. Emtricitabine and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) that act as chain terminators during viral DNA synthesis. Together, they provide potent suppression of HIV viral load when used as combination antiretroviral therapy.","oneSentence":"This combination of three antiretroviral drugs suppresses HIV replication by inhibiting reverse transcriptase and blocking viral integration into host cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:14.738Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"},{"name":"HIV-1 infection as part of combination antiretroviral therapy"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT02591420","phase":"PHASE1","title":"Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT01778413","phase":"PHASE4","title":"Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine","status":"COMPLETED","sponsor":"Anna Cruceta","startDate":"2013-06-03","conditions":"HIV","enrollment":61},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT02652260","phase":"PHASE2","title":"Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-03-04","conditions":"HIV-1, Central Nervous System","enrollment":86},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT02403674","phase":"PHASE3","title":"Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-05","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":734},{"nctId":"NCT01380080","phase":"PHASE4","title":"REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-10","conditions":"HIV Infection","enrollment":851},{"nctId":"NCT02722421","phase":"PHASE2","title":"Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-04-06","conditions":"HIV, Contraception","enrollment":28},{"nctId":"NCT06619288","phase":"","title":"Good-first: B/F/TAF As First-line ART","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-07-01","conditions":"HIV Infection","enrollment":630},{"nctId":"NCT03502005","phase":"PHASE4","title":"Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1","status":"COMPLETED","sponsor":"Midland Research Group, Inc.","startDate":"2018-03-01","conditions":"Human Immunodeficiency Virus","enrollment":100},{"nctId":"NCT01789879","phase":"PHASE2","title":"A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2014-03-04","conditions":"HIV, Contraception","enrollment":60},{"nctId":"NCT02475915","phase":"PHASE1, PHASE2","title":"Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection","status":"COMPLETED","sponsor":"SEARCH Research Foundation","startDate":"2015-01","conditions":"Acute HIV Infection","enrollment":15},{"nctId":"NCT00775606","phase":"PHASE4","title":"Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2008-10","conditions":"Acquired Immune Deficiency Syndrome","enrollment":15},{"nctId":"NCT03122262","phase":"PHASE3","title":"ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2017-01-16","conditions":"HIV-1 Infection","enrollment":1110},{"nctId":"NCT04296695","phase":"PHASE4","title":"Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-07-14","conditions":"HIV-1-infection","enrollment":250},{"nctId":"NCT03532425","phase":"PHASE4","title":"B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2018-10-29","conditions":"HIV-1-infection","enrollment":28},{"nctId":"NCT03048422","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-01-19","conditions":"HIV Infections","enrollment":643},{"nctId":"NCT01815580","phase":"PHASE4","title":"HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-07","conditions":"HIV","enrollment":225},{"nctId":"NCT04424264","phase":"PHASE1","title":"The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2019-12-05","conditions":"HIV-1-infection, Tuberculosis","enrollment":18},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT01435018","phase":"PHASE3","title":"Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-10-01","conditions":"HIV-1 Infection","enrollment":334},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01147107","phase":"PHASE4","title":"Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection","status":"COMPLETED","sponsor":"University of Hawaii","startDate":"2014-02","conditions":"Hepatitis C, Chronic, HIV Infection","enrollment":80},{"nctId":"NCT00344760","phase":"PHASE4","title":"A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2005-01","conditions":"HIV Infections","enrollment":2},{"nctId":"NCT01815736","phase":"PHASE3","title":"Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-03-27","conditions":"HIV, HIV Infections","enrollment":1443},{"nctId":"NCT01709084","phase":"PHASE3","title":"A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2013-10-02","conditions":"Human Immunodeficiency Virus-type 1 Infection","enrollment":426},{"nctId":"NCT02057796","phase":"PHASE4","title":"Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-09","conditions":"HIV-1 Infection","enrollment":1050},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00752856","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-08-26","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT03405194","phase":"NA","title":"Same-Day Treatment With Genvoya vs. EFV/TDF/3TC","status":"WITHDRAWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2018-05-01","conditions":"HIV/AIDS","enrollment":""},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT01011413","phase":"PHASE3","title":"Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2011-08","conditions":"HIV Infections","enrollment":636},{"nctId":"NCT03595709","phase":"PHASE3","title":"Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan","status":"COMPLETED","sponsor":"Yu-Jay Corp.","startDate":"2018-12-06","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT01641809","phase":"PHASE2","title":"Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-08-06","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":244},{"nctId":"NCT02345226","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-26","conditions":"HIV-1 Infection","enrollment":881},{"nctId":"NCT01352117","phase":"PHASE3","title":"Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-11-18","conditions":"HIV-1 Infection, Kaposi's Sarcoma","enrollment":192},{"nctId":"NCT01293123","phase":"NA","title":"Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2011-12","conditions":"HIV","enrollment":2},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT00335322","phase":"PHASE4","title":"ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2007-02","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":329},{"nctId":"NCT01632891","phase":"PHASE1, PHASE2","title":"Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-01-10","conditions":"HIV-1 Infection, Pf Subclinical Parasitemia","enrollment":52},{"nctId":"NCT01632345","phase":"PHASE2","title":"A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-12","conditions":"HIV Infections","enrollment":342},{"nctId":"NCT03251690","phase":"NA","title":"Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2016-10-27","conditions":"Anti-Retroviral Agents, Efavirenz, HIV-1-infection","enrollment":246},{"nctId":"NCT02946762","phase":"NA","title":"TasP in Correctional Facilities","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2016-02-01","conditions":"HIV, Tuberculosis","enrollment":419},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00442962","phase":"PHASE4","title":"HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2007-05","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT01403051","phase":"PHASE2","title":"High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-09","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT00118898","phase":"PHASE3","title":"Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-09","conditions":"HIV Infections","enrollment":1864},{"nctId":"NCT00108862","phase":"PHASE4","title":"Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2006-08","conditions":"HIV Infection, Tuberculosis","enrollment":809},{"nctId":"NCT00084136","phase":"PHASE4","title":"Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-05","conditions":"HIV Infections","enrollment":1571},{"nctId":"NCT02415595","phase":"PHASE2","title":"Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2015-05-12","conditions":"Infection, Human Immunodeficiency Virus","enrollment":210},{"nctId":"NCT02042001","phase":"PHASE4","title":"Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects","status":"COMPLETED","sponsor":"Azienda Ospedaliera San Gerardo di Monza","startDate":"2015-07-01","conditions":"Impaired Cognition, Depression/Anxiety, Poor Quality Sleep","enrollment":74},{"nctId":"NCT01263015","phase":"PHASE3","title":"A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-02-01","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":844},{"nctId":"NCT01891799","phase":"","title":"Swaziland Safe Generations","status":"COMPLETED","sponsor":"Columbia University","startDate":"2013-08","conditions":"HIV/AIDS","enrollment":2518},{"nctId":"NCT03256422","phase":"PHASE3","title":"Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-09-07","conditions":"HIV Infections","enrollment":640},{"nctId":"NCT00951015","phase":"PHASE2","title":"A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-07-30","conditions":"Infection, Human Immunodeficiency Virus","enrollment":208},{"nctId":"NCT02246998","phase":"PHASE4","title":"Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-12-15","conditions":"HIV-1 Infection","enrollment":72},{"nctId":"NCT01935830","phase":"EARLY_PHASE1","title":"LAAM-HAART PET Imaging","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-08","conditions":"Healthy Volunteers","enrollment":10},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT01231555","phase":"PHASE2","title":"Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2010-11-18","conditions":"Infection, Human Immunodeficiency Virus","enrollment":23},{"nctId":"NCT02499874","phase":"PHASE1","title":"SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-08","conditions":"HIV","enrollment":26},{"nctId":"NCT03309566","phase":"PHASE4","title":"Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir","status":"COMPLETED","sponsor":"Laboratorio Elea Phoenix S.A.","startDate":"2016-09-04","conditions":"Healthy","enrollment":24},{"nctId":"NCT00414635","phase":"PHASE4","title":"FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2006-08","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT02529059","phase":"PHASE4","title":"SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-11","conditions":"HIV","enrollment":40},{"nctId":"NCT02269462","phase":"","title":"A Study to Evaluate the Effects of Genetic Factors on the Pharmacokinetics of Antiretroviral Drugs During Pregnancy and Lactation","status":"COMPLETED","sponsor":"Adeniyi Olagunju","startDate":"2012-12","conditions":"HIV, Pregnancy, Breastfeeding","enrollment":460},{"nctId":"NCT01929759","phase":"NA","title":"Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-01","conditions":"HIV Disease","enrollment":10},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT02832778","phase":"PHASE1","title":"Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid","status":"UNKNOWN","sponsor":"St Stephens Aids Trust","startDate":"2016-11-21","conditions":"HIV","enrollment":35},{"nctId":"NCT02547844","phase":"PHASE4","title":"Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-09","conditions":"HIV-1","enrollment":30},{"nctId":"NCT01173510","phase":"PHASE4","title":"A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells","status":"WITHDRAWN","sponsor":"Community Research Initiative of New England","startDate":"2010-08-23","conditions":"HIV Infections, Acquired Immune Deficiency Syndrome","enrollment":""},{"nctId":"NCT00924898","phase":"PHASE4","title":"Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2005-01","conditions":"Acute HIV Infection, HIV Infections","enrollment":92},{"nctId":"NCT02447016","phase":"PHASE4","title":"Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera","status":"TERMINATED","sponsor":"Sheba Medical Center","startDate":"2015-05","conditions":"HIV","enrollment":25},{"nctId":"NCT00369941","phase":"PHASE3","title":"A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-08","conditions":"HIV Infections","enrollment":566},{"nctId":"NCT01040091","phase":"PHASE1","title":"Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-12","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT01509508","phase":"NA","title":"Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-03","conditions":"HIV Infection","enrollment":28153},{"nctId":"NCT02827643","phase":"NA","title":"Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2016-06","conditions":"Bone Density","enrollment":48},{"nctId":"NCT00734344","phase":"NA","title":"Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2008-09","conditions":"Acute HIV Infection","enrollment":18},{"nctId":"NCT00540449","phase":"PHASE3","title":"TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-05","conditions":"HIV Infections, HIV-1, Human Immunodeficiency Virus Type 1","enrollment":694},{"nctId":"NCT02283060","phase":"PHASE4","title":"Sleep and Cognition After Atripla to Stribild Switch","status":"UNKNOWN","sponsor":"University of Hawaii","startDate":"2014-09","conditions":"HIV","enrollment":30},{"nctId":"NCT01479634","phase":"NA","title":"Early HIV Therapy in Patients With High CD4 Cell Counts","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2011-10","conditions":"HIV","enrollment":279},{"nctId":"NCT01515813","phase":"PHASE2","title":"Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation","status":"WITHDRAWN","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-11","conditions":"HIV-1 Infection","enrollment":""},{"nctId":"NCT02157311","phase":"PHASE3","title":"4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-07","conditions":"HIV-1 Infection","enrollment":100},{"nctId":"NCT01495702","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-12","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":439},{"nctId":"NCT01322932","phase":"","title":"Tenofovir, Emtricitabine and Efavirenz Late Switch to a Single Pill: Patients' Opinion Survey","status":"COMPLETED","sponsor":"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","startDate":"2010-07","conditions":"HIV Infection","enrollment":95},{"nctId":"NCT01095796","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03","conditions":"HIV, HIV Infections","enrollment":707},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT00863668","phase":"NA","title":"Raltegravir Activity In Lymphoid Tissues","status":"WITHDRAWN","sponsor":"University of Minnesota","startDate":"2009-03","conditions":"HIV Infection, HIV Infections","enrollment":""},{"nctId":"NCT00984152","phase":"PHASE3","title":"Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2011-06","conditions":"HIV-1 Infections","enrollment":""},{"nctId":"NCT00737724","phase":"NA","title":"Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment","status":"TERMINATED","sponsor":"Instituto Nacional de Enfermedades Respiratorias","startDate":"2008-03","conditions":"HIV, AIDS, Tuberculosis","enrollment":63},{"nctId":"NCT01583439","phase":"NA","title":"The Mochudi Prevention Project ART Protocol","status":"TERMINATED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2012-09","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT01690403","phase":"PHASE1","title":"Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-12","conditions":"Tuberculosis","enrollment":25},{"nctId":"NCT01309243","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-02","conditions":"HIV-1 Infection","enrollment":799},{"nctId":"NCT01180075","phase":"","title":"Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-05","conditions":"Human Immunodeficiency Virus","enrollment":85}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DIZZINESS"},{"count":2,"reaction":"INSOMNIA"},{"count":2,"reaction":"MALAISE"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"VOMITING"},{"count":1,"reaction":"ADRENERGIC SYNDROME"},{"count":1,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"DRUG WITHDRAWAL SYNDROME"},{"count":1,"reaction":"EXPOSURE DURING PREGNANCY"},{"count":1,"reaction":"LIVE BIRTH"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["atripla"],"phase":"marketed","status":"active","brandName":"efavirenz + emtricitabina + tenofovir","genericName":"efavirenz + emtricitabina + tenofovir","companyName":"Hospital Universitari Vall d'Hebron Research Institute","companyId":"hospital-universitari-vall-d-hebron-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of three antiretroviral drugs suppresses HIV replication by inhibiting reverse transcriptase and blocking viral integration into host cells. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection as part of combination antiretroviral therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}